A common component of N-glycosylation at the Fc Asn-297 position is a fucose (hexose deoxy sugar) core; fucosylation is one of the most common oligosaccharide modifications of antibodies. However, mAbs with no fucose core (afucosylated) have increased efficacy in terms of antibody-dependent cellular cytotoxicity (ADCC), when compared to the equivalent fucosylated mAb.
Therefore, specific mammalian cell lines able to produce afucosylated mAbs have been developed to enable controlled fucosylation in future development of mAb biopharmaceuticals that require an ADCC response for optimal success.
Other post-translational modifications include o-linked glycosylation, usually involving smaller oligosaccharide units attached to serine or threonine residues and typically in the variable region. N-linked glycan PTMs are also found in the V and CH1 domains with the former variant usually involving sialic acids (NANA, NGNA).